Evidence map›Paper›PMID 38507053›Full record

ArticleEuropean radiology2024

Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.

Giulia Marvaso, Lars Johannes Isaksson, Mattia Zaffaroni, Maria Giulia Vincini, Paul Eugene Summers, Matteo Pepa, Giulia Corrao, Giovanni Carlo Mazzola, Marco Rotondi, Federico Mastroleo and 16 more

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. End-to-end [Abdominal radiology (New York) · 2025
    Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Giulia MarvasoDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Lars Johannes IsakssonDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Mattia ZaffaroniDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. mattia.zaffaroni@ieo.it.
Maria Giulia VinciniDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. mariagiulia.vincini@ieo.it.ORCID http://orcid.org/0000-0001-7830-3149
Paul Eugene SummersDivision of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Matteo PepaDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Giulia CorraoDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Giovanni Carlo MazzolaDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Marco RotondiDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Federico MastroleoDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Sara RaimondiDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Sarah AlessiDivision of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Paola PricoloDivision of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Stefano LuzzagoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Francesco Alessandro MistrettaDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Matteo FerroDivision of Urology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Federica CattaniMedical Physics Unit, IEO European Institute of Oncology IRCCS, Milan, Italy.
Francesco CeciDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Gennaro MusiDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Ottavio De CobelliDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Marta CremonesiRadiation Research Unit, IEO European Institute of Oncology IRCCS, Milan, Italy.
Sara GandiniDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Davide La TorreDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Roberto OrecchiaScientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy.
Giuseppe PetraliaDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Barbara Alicja Jereczek-FossaDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo test the ability of high-performance machine learning (ML) models employing clinical, radiological, and radiomic variables to improve non-invasive prediction of the pathological status of prostate cancer (PCa) in a large, single-institution cohort.

methodsPatients who underwent multiparametric MRI and prostatectomy in our institution in 2015-2018 were considered; a total of 949 patients were included. Gradient-boosted decision tree models were separately trained using clinical features alone and in combination with radiological reporting and/or prostate radiomic features to predict pathological T, pathological N, ISUP score, and their change from preclinical assessment. Model behavior was analyzed in terms of performance, feature importance, Shapley additive explanation (SHAP) values, and mean absolute error (MAE). The best model was compared against a naïve model mimicking clinical workflow.

resultsThe model including all variables was the best performing (AUC values ranging from 0.73 to 0.96 for the six endpoints). Radiomic features brought a small yet measurable boost in performance, with the SHAP values indicating that their contribution can be critical to successful prediction of endpoints for individual patients. MAEs were lower for low-risk patients, suggesting that the models find them easier to classify. The best model outperformed (p ≤ 0.0001) clinical baseline, resulting in significantly fewer false negative predictions and overall was less prone to under-staging.

conclusionsOur results highlight the potential benefit of integrative ML models for pathological status prediction in PCa. Additional studies regarding clinical integration of such models can provide valuable information for personalizing therapy offering a tool to improve non-invasive prediction of pathological status. CLINICAL RELEVANCE STATEMENT: The best machine learning model was less prone to under-staging of the disease. The improved accuracy of our pathological prediction models could constitute an asset to the clinical workflow by providing clinicians with accurate pathological predictions prior to treatment. KEY POINTS: • Currently, the most common strategies for pre-surgical stratification of prostate cancer (PCa) patients have shown to have suboptimal performances. • The addition of radiological features to the clinical features gave a considerable boost in model performance. Our best model outperforms the naïve model, avoiding under-staging and resulting in a critical advantage in the clinic. •Machine learning models incorporating clinical, radiological, and radiomics features significantly improved accuracy of pathological prediction in prostate cancer, possibly constituting an asset to the clinical workflow.

Indexed as

Machine LearningMultiparametric Magnetic Resonance ImagingProstatectomyProstatic NeoplasmsAgedDecision TreesHumansMaleMiddle AgedPredictive Value of TestsProstateRadiomicsRetrospective StudiesMachine learningModels (statistical)Multiparametric magnetic resonance imagingProstate cancerRadiomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.